Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now

Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now


A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women’s Clinic in Carbondale, Illinois, April 20, 2023.

Evelyn Hockstein | Reuters

A federal appeals court on Wednesday imposed restrictions on the abortion pill mifepristone, though the ruling will not have an immediate impact.

The order by the U.S. 5th Circuit Court of Appeals is almost certain to be appealed to the Supreme Court. Justice Samuel Alito in April preemptively paused any ruling from the appeals court pending a petition for the high court to take the case.

If the Supreme Court does not take the case, the restrictions will go into effect.

The court battle over mifepristone comes more than a year after the Supreme Court abolished federal abortion rights by overturning the landmark 1973 Roe v. Wade ruling.

Mifepristone, used in combination with another drug called misoprostol, is the most common method to terminate a pregnancy in the U.S.

A panel of three judges at the 5th Circuit heard arguments May 17 from lawyers representing the Food and Drug Administration, mifepristone distributor Danco Laboratories, and a group of anti-abortion doctors called the Alliance for Hippocratic Medicine.

The judges were all appointed by Republican presidents. Judges James Ho and Cory Wilson were appointed by Donald Trump. Judge Jennifer Elrod was appointed by George W. Bush.

The FDA and Danco argued that the lawsuit seeking to pull mifepristone from the U.S. market is unprecedented, has no basis in science and will jeopardize women’s health.

The panel of judges pushed back hard on those arguments.

The judges questioned whether allowing women to receive mifepristone by mail without having to see a doctor would result in more patients seeking emergency care. Ho pushed back on the FDA and Danco’s characterization of the case as unprecedented.

“I don’t understand this theme — the FDA can do no wrong. That is basically the narrative you all are putting forth — nobody should ever question the FDA,” Ho said during Wednesday’s hearing.

“We are allowed to look at the FDA just like we are allowed to look at any agency, that’s the role of the courts,” Ho said. 

This is breaking news. Please check back for updates.



Source

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
Health

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”  “They’re going to be tariffs […]

Read More